GlassScriptPhysician profile
Laura Fay
NPI 1497190953
$8,747.60
in general payments reported to CMS, 2019-2025
41 companies · $1,252 in 2025
The $1,252 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,102 · 2020: $613 · 2021: $830 · 2022: $1,227 · 2023: $1,881 · 2024: $1,842 · 2025: $1,252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,876 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,876.36 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,392.43 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $1,095.81 | 2019-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $1,018.34 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $733.69 | 2019-2025 | |
| Abbvie INC. | $477.16 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $469.69 | 2019-2025 | Enhertu, Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $423.74 | 2022-2025 | |
| Amgen INC. | $387.40 | 2019-2025 | Repatha, Otezla, Evenity |
| Dexcom, INC. | $354.35 | 2021-2025 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $289.22 | 2019-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $278.48 | 2019-2025 | Jardiance |
| Abbott Laboratories | $263.74 | 2021-2025 | Freestyle Libre 3, Freestyle Libre |
| Otsuka America Pharmaceutical, INC. | $149.46 | 2023-2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $136.95 | 2019-2021 | |
| Exact Sciences Corporation | $131.48 | 2023-2024 | Cologuard Collection Kit |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Fay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.